Abbott Laboratories Aktie
WKN: 850103 / ISIN: US0028241000
13.11.2023 18:28:41
|
Abbott Says Aspirin-free Medication Regimen Benefits People With HeartMate 3 Heart Pump
(RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump.
According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.
The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump.
The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The HeartMate 3 patients who did not take aspirin spent 47% fewer days in the hospital due to a nearly 40% decrease in bleeding events compared to patients who continued to take aspirin daily.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abbott Laboratoriesmehr Nachrichten
24.07.25 |
NASDAQ Composite Index-Papier Abbott Laboratories-Aktie: So viel Gewinn hätte ein Investment in Abbott Laboratories von vor einem Jahr eingebracht (finanzen.at) | |
18.07.25 |
Minuszeichen in New York: So entwickelt sich der S&P 500 am Freitagnachmittag (finanzen.at) | |
18.07.25 |
NASDAQ-Handel: NASDAQ Composite legt zum Start des Freitagshandels zu (finanzen.at) | |
17.07.25 |
Börse New York: NASDAQ Composite beendet den Handel im Plus (finanzen.at) | |
17.07.25 |
Zuversicht in New York: S&P 500 zeigt sich letztendlich fester (finanzen.at) | |
17.07.25 |
Gewinne in New York: NASDAQ Composite legt zu (finanzen.at) | |
17.07.25 |
S&P 500 aktuell: Am Nachmittag Pluszeichen im S&P 500 (finanzen.at) | |
17.07.25 |
Aufschläge in New York: S&P 500 am Donnerstagmittag fester (finanzen.at) |
Analysen zu Abbott Laboratoriesmehr Analysen
Aktien in diesem Artikel
Abbott Laboratories | 111,98 | 1,56% |
|